Fair Value Measurements - Schedule of Contingent Consideration Earnout Expect to be Required to Settle Include Significant Unobservable Inputs (Detail) - Contingent Consideration - USD ($) $ in Thousands		Sep. 30, 2023	Dec. 31, 2022
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Liabilities, fair value		$ 26,348	$ 65,509
Revenue and Volume Based Payments | Monte Carlo Simulation | Fair Value, Recurring
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Liabilities, fair value		$ 1,460
Revenue and Volume Based Payments | Monte Carlo Simulation | Fair Value, Recurring | Earnout Discount Rate
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Weighted average discount rate	[1]	6.50%
Revenue and Volume Based Payments | Monte Carlo Simulation | Fair Value, Recurring | Volatility
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Weighted average discount rate	[1]	21.70%
Revenue and Volume Based Payments | Monte Carlo Simulation | Fair Value, Recurring | Revenue & Volume Discount Rate
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Weighted average discount rate	[1]	8.20%
Manufacturing line expansions | Monte Carlo Simulation | Fair Value, Recurring
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Probability of success		100.00%
Manufacturing line expansions | Monte Carlo Simulation | Fair Value, Recurring | Probability of Success
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Weighted average discount rate	[1]	100.00%
Manufacturing line expansions | Probability-Weighted Present Value [Member] | Fair Value, Recurring
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Liabilities, fair value		$ 5,505
Manufacturing line expansions | Probability-Weighted Present Value [Member] | Fair Value, Recurring | Earnout Discount Rate
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Weighted average discount rate	[1]	6.30%
Minimum | Revenue and Volume Based Payments | Monte Carlo Simulation | Fair Value, Recurring
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Discount Rate		6.10%
Volatility		13.10%
Revenue and volume discount rate		5.10%
Minimum | Manufacturing line expansions | Probability-Weighted Present Value [Member] | Fair Value, Recurring
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Discount Rate		6.10%
Maximum | Revenue and Volume Based Payments | Monte Carlo Simulation | Fair Value, Recurring
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Discount Rate		7.10%
Volatility		24.60%
Revenue and volume discount rate		9.30%
Maximum | Manufacturing line expansions | Probability-Weighted Present Value [Member] | Fair Value, Recurring
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Discount Rate		6.40%
Avitide and FlexBiosys | Monte Carlo Simulation | Fair Value, Recurring
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Liabilities, fair value		$ 19,383
Probability of success		100.00%
Avitide and FlexBiosys | Monte Carlo Simulation | Fair Value, Recurring | Probability of Success
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Weighted average discount rate	[1]	100.00%
Avitide and FlexBiosys | Monte Carlo Simulation | Fair Value, Recurring | Earnout Discount Rate
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Weighted average discount rate	[1]	7.10%
Avitide and FlexBiosys | Minimum | Monte Carlo Simulation | Fair Value, Recurring
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Discount Rate		7.10%

[1] Unobservable inputs were weighted by the relative fair value of the contingent consideration liability.